Rekah Pharmaceutical Industry Ltd
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements, and medical devices in Israel. The company offers steroids, antibiotics, and ophthalmic products, as well as dermo-cosmetics products. Its portfolio of products comprise Rx and OTC drugs, and medical devices used in various therapeut… Read more
Rekah Pharmaceutical Industry Ltd (REKA) - Total Assets
Latest total assets as of September 2025: ILA414.67 Million ILA
Based on the latest financial reports, Rekah Pharmaceutical Industry Ltd (REKA) holds total assets worth ILA414.67 Million ILA as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Rekah Pharmaceutical Industry Ltd - Total Assets Trend (2004–2024)
This chart illustrates how Rekah Pharmaceutical Industry Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Rekah Pharmaceutical Industry Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Rekah Pharmaceutical Industry Ltd's total assets of ILA414.67 Million consist of 51.2% current assets and 48.8% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 1.6% |
| Accounts Receivable | ILA129.35 Million | 28.9% |
| Inventory | ILA82.48 Million | 18.4% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA60.84 Million | 13.6% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how Rekah Pharmaceutical Industry Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rekah Pharmaceutical Industry Ltd's current assets represent 51.2% of total assets in 2024, an increase from 0.0% in 2004.
- Cash Position: Cash and equivalents constituted 1.6% of total assets in 2024, up from 1.2% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 2.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 28.9% of total assets.
Rekah Pharmaceutical Industry Ltd Competitors by Total Assets
Key competitors of Rekah Pharmaceutical Industry Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Rekah Pharmaceutical Industry Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Rekah Pharmaceutical Industry Ltd generates 0.72x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Rekah Pharmaceutical Industry Ltd generates $ 1.39 in net profit.
Rekah Pharmaceutical Industry Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.65 | 1.43 | 2.10 |
| Quick Ratio | 0.90 | 0.89 | 1.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA83.12 Million | ILA 69.51 Million | ILA 119.09 Million |
Rekah Pharmaceutical Industry Ltd - Advanced Valuation Insights
This section examines the relationship between Rekah Pharmaceutical Industry Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.90 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -7.7% |
| Total Assets | ILA447.22 Million |
| Market Capitalization | $385.28K USD |
Valuation Analysis
Below Book Valuation: The market values Rekah Pharmaceutical Industry Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Rekah Pharmaceutical Industry Ltd's assets decreased by 7.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Rekah Pharmaceutical Industry Ltd (2004–2024)
The table below shows the annual total assets of Rekah Pharmaceutical Industry Ltd from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA447.22 Million | -7.74% |
| 2023-12-31 | ILA484.72 Million | +8.10% |
| 2022-12-31 | ILA448.42 Million | +2.59% |
| 2021-12-31 | ILA437.09 Million | +4.15% |
| 2020-12-31 | ILA419.69 Million | +14.32% |
| 2019-12-31 | ILA367.11 Million | +22.26% |
| 2018-12-31 | ILA300.28 Million | +1.81% |
| 2017-12-31 | ILA294.95 Million | -8.61% |
| 2016-12-31 | ILA322.72 Million | -0.34% |
| 2015-12-31 | ILA323.82 Million | +4.42% |
| 2014-12-31 | ILA310.11 Million | +2.29% |
| 2013-12-31 | ILA303.16 Million | +1.71% |
| 2012-12-31 | ILA298.07 Million | +3.86% |
| 2011-12-31 | ILA286.99 Million | -0.34% |
| 2010-12-31 | ILA287.97 Million | +3.44% |
| 2009-12-31 | ILA278.40 Million | -4.16% |
| 2008-12-31 | ILA290.50 Million | -3.48% |
| 2007-12-31 | ILA300.96 Million | +1.49% |
| 2006-12-31 | ILA296.53 Million | +11.06% |
| 2005-12-31 | ILA267.00 Million | +32.15% |
| 2004-12-31 | ILA202.04 Million | -- |